Ganirelix

CHEMBL1251 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1570.3 g/mol

LogP

5.4

Phase

4

This medication is a synthetic hormone that blocks the action of gonadotropin-releasing hormone to prevent premature ovulation during fertility treatments. By suppressing the LH surge, it allows controlled timing of egg retrieval in women undergoing assisted reproduction.

Masse moléculaire

1570,3000 g/mol

LogP

5,40

TPSA

451,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Endometriosis Endocrinology Hypertension Breast Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

InChI

InChI=1S/C80H113ClN18O13/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+/m1/s1

Molecular Formula

C80H113ClN18O13

HBD / HBA

16 / 16

Liaisons Rotatives

48

Atomes Lourds

112

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This medication is a synthetic hormone that blocks the action of gonadotropin-releasing hormone to prevent premature ovulation during fertility treatments. By suppressing the LH surge, it allows controlled timing of egg retrieval in women undergoing assisted reproduction.

Yes, Ganirelix is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1251. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16130957. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Ganirelix sur PillFYI

Structure

Données Clés

Formule: C80H113ClN18O13
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.